Article Text

PDF
Extended report
Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis
  1. Katja Thiele1,
  2. Dörte Huscher1,2,
  3. Sascha Bischoff1,
  4. Susanna Späthling-Mestekemper3,
  5. Marina Backhaus2,
  6. Martin Aringer4,
  7. Thomas Kohlmann5,
  8. Angela Zink1,2,
  9. for the German Collaborative Arthritis Centres
  1. 1Epidemiology Unit, German Rheumatism Research Centre, A Leibniz Institute, Berlin, Germany
  2. 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
  3. 3Rheumatologist in Private Practice, Munich, Germany
  4. 4Department of Rheumatology, Technical University of Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
  5. 5Institute for Community Medicine, Ernst-Moritz-Arndt-University of Greifswald, Greifswald, Germany
  1. Correspondence to Katja Thiele, Epidemiology Unit, German Rheumatism Research Centre, A Leibniz Institute, Charitéplatz 1, Berlin 10117, Germany; thiele{at}drfz.de

Abstract

Objective To compare the performance of the preliminary American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria with the 28-joint count Disease Activity Score (DAS28) remission in unselected ‘real-life’ patients.

Methods Remission was calculated according to the DAS28 and to both versions of the ACR/EULAR criteria (Boolean or Simplified Disease Activity Index (SDAI)-based) for 6864 patients with rheumatoid arthritis (RA) who were enrolled in the national database of the German Collaborative Arthritis Centres between 2007 and 2009. Logistic regression analyses identified factors that were responsible for patients in DAS28 remission to miss the new criteria. In addition, the functional status of patients who fulfilled the different remission criteria was compared with that of an age- and sex-matched population sample.

Results Of all patients, 28% were in DAS28, 7% in Boolean and 11% in SDAI remission. Of those in DAS28 remission, 21.0% were also in Boolean and 34% also in SDAI remission. Higher scores for pain and fatigue, the presence of degenerative spine disease, longer disease duration and male gender were significantly associated with missing the new criteria despite being in DAS28 remission. Compared with age- and sex-matched samples from the general population, patients in DAS28 remission had a similar functional ability while patients in remission according to the new criteria had better functional scores.

Conclusions Patients fulfilling the new remission criteria tend to be not only free from active RA, but also from other disabling diseases. If these criteria are applied in clinical practice to guide treatment decisions, the impact of comorbidity should be taken into account.

  • DAS28
  • Rheumatoid Arthritis
  • Epidemiology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.